{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:03:40Z","timestamp":1761901420498,"version":"build-2065373602"},"reference-count":2,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.msard.2018.12.027","type":"journal-article","created":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T03:24:49Z","timestamp":1545189889000},"page":"154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Response to correspondence: \u201cInterferon alpha might be an alternative therapeutic choice for refractory neuro-Beh\u00e7et's disease\u201d \u2013 Authors reply"],"prefix":"10.1016","volume":"29","author":[{"given":"Fr\u00e9d\u00e9ric","family":"London","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Duprez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"van Pesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2018.12.027_bib0001","article-title":"Interferon alpha might be an alternative therapeutic choice for refractory neuro-Beh\u00e7et's disease","author":"Bolek","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2018.12.027_bib0002","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.msard.2018.10.117","article-title":"Which treatment strategies for polyrefractory neuro-Beh\u00e7et disease?","volume":"27","author":"London","year":"2018","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818305571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818305571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:45:09Z","timestamp":1761900309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818305571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":2,"alternative-id":["S2211034818305571"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.12.027","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to correspondence: \u201cInterferon alpha might be an alternative therapeutic choice for refractory neuro-Beh\u00e7et's disease\u201d \u2013 Authors reply","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}